Valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 51655-389

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 51655-389). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (51655 389 52 Rev A 03 23)

Label (51655 389 52 Rev A 03 23)
This is a description of Valsartan and Hydrochlorothiazide Tablets, USP which comes in a packaging of 30 tablets. The tablets contain 160mg of Valsartan and 12.5mg of Hydrochlorothiazide, packed in a container. The dosage information is mentioned in the package insert. The tablets should be stored at 20° - 25°C (68° - 77°F) and should be kept away from heat and moisture. The packaging is done by Northwind Pharmaceuticals and repackaged from Mylan Pharmaceuticals Inc. The text has details of the NDC, Lot number, and other useful information for medicinal purposes.*
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)

Figure 1: Probability Of Achieving Systolic Blood Pressure Less Than 140 Mmhg At Week 8 (Image 01)
This is a study report with some numerical values showing the baseline SBP (mmHg), hydrochlorothiazide dosage of 25mg, and some graphs representing blood pressure levels. The text also mentions "SBP<140 (mmHg)" which could indicate a target value for blood pressure in the study.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)

Figure 2: Probability Of Achieving Diastolic Blood Pressure Less Than 90 Mmhg At Week 8 (Image 02)
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)

Figure 3: Probability Of Achieving Systolic Blood Pressure Less Than 130 Mmhg At Week 8 (Image 03)
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)

Figure 4: Probability Of Achieving Diastolic Blood Pressure Less Than 80 Mmhg At Week 8 (Image 04)
This is a medical document that lists the medication dosage and baseline readings for an individual. It includes medications such as Valsartan and Hydrochlorothiazide, with a note about DBP (Diastolic Blood Pressure) being below 80 mmHg.*
FDA Label Image

Valsartan Structural Formula (Image 05)

Valsartan Structural Formula (Image 05)
FDA Label Image

Hydrochlorothiazide Structural Formula (Image 06)

Hydrochlorothiazide Structural Formula (Image 06)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.